Positive News SentimentPositive NewsNASDAQ:CSTL Castle Biosciences (CSTL) Stock Price, News & Analysis $16.50 +0.10 (+0.61%) Closing price 05/20/2025 04:00 PM EasternExtended Trading$16.50 0.00 (0.00%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Castle Biosciences Stock (NASDAQ:CSTL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Castle Biosciences alerts:Sign Up Key Stats Today's Range$16.22▼$16.5650-Day Range$16.32▼$21.9852-Week Range$15.70▼$35.84Volume244,623 shsAverage Volume403,461 shsMarket Capitalization$476.39 millionP/E Ratio82.50Dividend YieldN/APrice Target$37.50Consensus RatingBuy Company OverviewCastle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.Read More… Castle Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreCSTL MarketRank™: Castle Biosciences scored higher than 47% of companies evaluated by MarketBeat, and ranked 613th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCastle Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCastle Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about Castle Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Castle Biosciences are expected to decrease in the coming year, from $0.44 to ($1.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Castle Biosciences is 82.50, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.12.Price to Earnings Ratio vs. SectorThe P/E ratio of Castle Biosciences is 82.50, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.83.Price to Book Value per Share RatioCastle Biosciences has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Castle Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.23% of the outstanding shares of Castle Biosciences have been sold short.Short Interest Ratio / Days to CoverCastle Biosciences has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Castle Biosciences has recently increased by 3.42%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCastle Biosciences does not currently pay a dividend.Dividend GrowthCastle Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.23% of the outstanding shares of Castle Biosciences have been sold short.Short Interest Ratio / Days to CoverCastle Biosciences has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Castle Biosciences has recently increased by 3.42%, indicating that investor sentiment is decreasing. News and Social Media3.2 / 5News Sentiment1.71 News SentimentCastle Biosciences has a news sentiment score of 1.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Castle Biosciences this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for CSTL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Castle Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Castle Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $553,030.00 in company stock.Percentage Held by InsidersOnly 6.50% of the stock of Castle Biosciences is held by insiders.Percentage Held by Institutions92.60% of the stock of Castle Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Castle Biosciences' insider trading history. Receive CSTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CSTL Stock News HeadlinesCastle Biosciences to Present at the 2025 Jefferies Global Healthcare ConferenceMay 21 at 7:00 AM | globenewswire.comReal-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class ResultMay 9, 2025 | globenewswire.comHow to spot the exact time a stock tends to surge… or drop.Most folks have the idea of trading all wrong… And it honestly isn’t their fault. Look, we’ve seen the top traders at Wall Street pass on the narrative that you need to be a 100% savvy trader… or sit close to the charts all day just to target opportunities from the market… But in reality, you don’t need to do all that. In fact, according to a top trader who started using trading software before he could drive a car… studied technical analysis under two top minds in finance… And despite being 30 this year, he already has a decade of trading experience under his belt!May 21, 2025 | ProsperityPub (Ad)Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2025 Earnings Call TranscriptMay 7, 2025 | msn.comCastle Biosciences Celebrates Skin Cancer Awareness MonthMay 7, 2025 | globenewswire.comCastle Biosciences, Inc.: Castle Biosciences to Acquire PreviseMay 6, 2025 | finanznachrichten.deCastle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call TranscriptMay 5, 2025 | seekingalpha.comCastle Biosciences Reports First Quarter 2025 ResultsMay 5, 2025 | globenewswire.comSee More Headlines CSTL Stock Analysis - Frequently Asked Questions How have CSTL shares performed this year? Castle Biosciences' stock was trading at $26.65 at the beginning of the year. Since then, CSTL stock has decreased by 38.1% and is now trading at $16.50. View the best growth stocks for 2025 here. How were Castle Biosciences' earnings last quarter? Castle Biosciences, Inc. (NASDAQ:CSTL) issued its quarterly earnings results on Monday, May, 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by $0.12. The firm earned $87.99 million during the quarter, compared to analyst estimates of $80.40 million. Castle Biosciences had a trailing twelve-month return on equity of 1.47% and a net margin of 1.95%. Read the conference call transcript. When did Castle Biosciences IPO? Castle Biosciences (CSTL) raised $50 million in an IPO on Thursday, July 25th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. SVB Leerink and Baird served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. Who are Castle Biosciences' major shareholders? Castle Biosciences' top institutional shareholders include Vanguard Group Inc. (7.09%), Principal Financial Group Inc. (5.09%), Wellington Management Group LLP (2.87%) and Nuveen LLC (2.33%). Insiders that own company stock include Kristen M Oelschlager, Derek J Maetzold, Tobin W Juvenal, Frank Stokes, Ellen Goldberg, Tiffany Olson and Daniel Bradbury. View institutional ownership trends. How do I buy shares of Castle Biosciences? Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Castle Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Castle Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), PayPal (PYPL), Adobe (ADBE), Advanced Micro Devices (AMD) and Broadcom (AVGO). Company Calendar Last Earnings5/05/2025Today5/21/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:CSTL CIK1447362 Webcastlebiosciences.com Phone(866) 788-9007FaxN/AEmployees540Year FoundedN/APrice Target and Rating Average Stock Price Target$37.50 High Stock Price Target$44.00 Low Stock Price Target$30.00 Potential Upside/Downside+127.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.19) Trailing P/E Ratio82.50 Forward P/E Ratio37.50 P/E GrowthN/ANet Income$-57,470,000.00 Net Margins1.95% Pretax Margin3.57% Return on Equity1.47% Return on Assets1.27% Debt Debt-to-Equity Ratio0.02 Current Ratio7.78 Quick Ratio7.64 Sales & Book Value Annual Sales$347.08 million Price / Sales1.37 Cash FlowN/A Price / Cash FlowN/A Book Value$14.54 per share Price / Book1.13Miscellaneous Outstanding Shares28,872,000Free Float25,990,000Market Cap$476.39 million OptionableOptionable Beta1.19 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:CSTL) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.